No Data
Beijing Science Sun Pharmaceutical: 2025 First Quarter Report
Beijing Science Sun Pharmaceutical (300485.SZ): In the first quarter, the net income was 39.97 million yuan, turning a profit year-on-year.
Gelonghui, April 23, Beijing Science Sun Pharmaceutical (300485.SZ) announced the first quarter report, with revenue of 92.5365 million yuan, a year-on-year decrease of 15.52%. The net income attributable to shareholders of the listed company was 39.97 million yuan, turning around from losses year-on-year, while the net income attributable to shareholders of the listed company, excluding non-recurring gains and losses, was 1.19 million yuan, a year-on-year decrease of 92.15%.
Beijing Science Sun Pharmaceutical (300485.SZ): Junyuan Pharmaceutical has successfully passed the recognition as a high-tech enterprise.
On April 10, Gelonghui reported that Beijing Science Sun Pharmaceutical (300485.SZ) announced that its subsidiary Shenyang Junyuan Pharmaceutical Co., Ltd. (referred to as "Junyuan Pharmaceutical") recently received the "High-tech Enterprise Certificate" issued jointly by the Liaoning Provincial Department of Science and Technology, the Liaoning Provincial Department of Finance, and the State Taxation Administration of Liaoning Province. The certificate number is GR202421000716, the issuance date is November 27, 2024, and the validity period is three years.
Beijing Science Sun Pharmaceutical (300485.SZ): does not involve Business in the field of synthetic biology.
On April 7, Gelonghui reported that Beijing Science Sun Pharmaceutical (300485.SZ) stated on the investor interaction platform that the company is currently not involved in synthetic biology Business, and it does not rule out making related arrangements in line with the company's future development.
Brokerage morning meeting highlights: The USA has increased tariffs on China, but the impact on these industries in the A-shares may be limited.
In today's brokerage morning meeting, GF SEC believes that the USA's tariffs on China have a limited impact on the A-share Computer Industry; China Securities Co.,Ltd. suggested being Bullish on the Innovative Drugs industry that is currently not affected by tariffs; Galaxy Securities stated that Deep Sea Technology has entered a new stage in Global Strategy, focusing on opportunities in core equipment.
Saisheng Pharmaceutical: 2024 Annual Report Summary
